Genmab — Marts 2015
-
Fra Nordeas eftermiddagskommentar" Genmab stiger 5%. Biotekselskabet Pharmacyclics, der arbejder inden for samme
område som Genmab, har nu fået et konkret bud fra amerikanske AbbVie. Buddet
lyder på USD 261,25 pr. aktie (+13,4%) eller +39% siden Bloomberg afslørede at en
mulig handel kunne være på vej for lidt over en uge siden. Johnson & Johnson, der
har et samarbejde med Pharmacyclics omkring udviklingen af Imbruvia mod leukæmi,skulle ifølge rygter også have været med i opløbet om et køb, men
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind

